INVO Fertility (IVF) Net Income towards Common Stockholders (2011 - 2026)

INVO Fertility (IVF) has reported Net Income towards Common Stockholders for 16 consecutive years, with -$1.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 89.02% year-over-year to -$1.7 million; the TTM figure through Mar 2026 stood at -$9.1 million (up 61.39% YoY), while the FY2025 annual figure was -$15.9 million, down 70.24% from the prior year.
• Net Income towards Common Stockholders declined to -$1.7 million in Q1 2026 per IVF's latest filing, from $541247.0 in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $541247.0 in Q4 2025 and bottomed at -$15.9 million in Q1 2025.
• Historically, Net Income towards Common Stockholders has averaged -$3.1 million across 5 years, with a median of -$2.5 million in 2022.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders plunged 2818.28% — and 2025, when it soared 113.97%.
• INVO Fertility's Net Income towards Common Stockholders stood at -$2.8 million in 2022, then rose by 28.98% to -$2.0 million in 2023, then sank by 97.15% to -$3.9 million in 2024, then jumped by 113.97% to $541247.0 in 2025, then slumped by 422.92% to -$1.7 million in 2026.
• Business Quant data shows IVF's Net Income towards Common Stockholders at -$1.7 million in Q1 2026, $541247.0 in Q4 2025, and -$2.6 million in Q3 2025.